Targeted radionuclide therapies, using radiolabeled peptides capable of binding to receptors overexpressed by cancer cells or radiolabeled antibodies for tumor-specific antigens, and therapies directed against the Epidermal Growth Factor Receptor (EGFR) [4,5] have been proposed as viable alternatives to chemotherapy and external beam radiation therapies. Here, EGFR is linked to neoplasm.